GlobeNewswire

Compuware: Survey Shows Critical Mainframe Workloads Increasing While Mainframe Staff Losses Remain Unfilled

Dela

Many Organizations Not Measuring, Prioritizing Vital Key Performance Indicators

  • 57 percent of enterprises with a mainframe currently run more than half of their business-critical applications on the platform-with that number expected to increase to 64 percent by next year.
  • 72 percent of customer-facing applications are completely or very dependent on mainframe processing.
  • Enterprises have only replaced 37 percent of the mainframe workforce lost over the past five years.
  • Many organizations surveyed are not currently measuring velocity or efficiency key performance indicators, putting them at a disadvantage in the digital age.

DETROIT, March 22, 2018 (GLOBE NEWSWIRE) -- The mainframe is becoming more important to large enterprises, with the percentage of organizations running at least half their business-critical applications on that platform expected to increase next year. However, the loss of skilled mainframe staff, and the failure to subsequently fill these positions, pose significant threats to application quality, velocity and efficiency.

These are among the findings of research and analysis conducted by Forrester Consulting on behalf of Compuware.  According to the study, "As mainframe workload increases-driven by modern analytics, blockchain and more mobile activity hitting the platform-customer-obsessed companies should seek to modernize application delivery and remove roadblocks to innovation."

The survey of mainframe decision-makers and developers in the U.S. and Europe also revealed:

  • Growing mainframe importance
    • 64 percent of enterprises surveyed will run more than half of their critical applications on the platform within the next year, up from 57 percent this year.
    • 72 percent of customer-facing applications at these enterprises are completely or very reliant on mainframe processing.
       
  • Loss of essential mainframe staff
    • Enterprises have lost an average 23 percent of specialized mainframe staff in the last five years.
    • 63 percent of those positions have not been filled. 
  • Failure to prioritize velocity and efficiency
    • While 55 percent of respondents cite application quality as "extremely important," only 42 percent put the same emphasis on development velocity and 46 percent on efficiency.
       
  • Failure to measure critical KPIs
    • While firms recognize the importance of quality, velocity and efficiency, significant percentages are not measuring them (Quality: 27 percent, Velocity: 38 percent, and Efficiency: 39 percent).
       
  • Customer experience disconnect
    • 59 percent say that improvements in quality, velocity and efficiency mean a better customer experience; yet only 31 percent see this focus actually decreasing customer-discovered defects.

These findings and others suggest that mainframe investments, culture and management practices need to evolve significantly in light of changing market realities. Insufficient emphasis on velocity, for example, is a holdover from an earlier era that predates the demands of today's fast-paced digital economy. Inadequate attention to efficiency likewise reflects an era when the mainframe development and quality assurance staffs were significantly larger and extraordinarily stable.

According to the Forrester study, "Mainframe is alive and growing at the heart of many businesses. IT decision makers cannot afford to treat their mainframe applications as static environments bound by long release cycles, nor can they fail to respond to their critical dependence on a retiring workforce. Instead, firms must implement the modern tools necessary to accelerate not only the quality, but the speed and efficiency, of their mainframe, as well as draw skilled people to work on the platform."

The complete Forrester Opportunity Snapshot study, entitled "Modern Mainframe KPIs Are Key To A Successful Digital Strategy," can be found here.

"Many enterprise CIOs are clearly facing a do-or-die moment when it comes to the mainframe," said Chris O'Malley, CEO of Compuware. "They must quickly re-think, re-design and re-tool their approach to mainframe DevOps or face a future where they are simply too slow and inflexible to keep pace with their more nimble competitors."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com .

Follow us on:

Press Contacts
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum